# Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China

> **NCT05110261** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 800 (actual)

## Conditions studied

- Lower Respiratory Tract Infection

## Interventions

- **DRUG:** Nirsevimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05110261
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-24
- **Primary completion:** 2025-11-24
- **Final completion:** 2025-11-24
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05110261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05110261, "Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05110261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*